Harbin Gloria Pharmaceuticals (002437) — Cash Flow Reinvestment Rate
Harbin Gloria Pharmaceuticals (002437) has a Cash Flow Reinvestment Rate of 0.02x as of September 2025, reinvesting CN¥4.26 Million (capex CN¥4.26 Million ) from operating cash flow of CN¥182.89 Million. Explore Harbin Gloria Pharmaceuticals capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Harbin Gloria Pharmaceuticals Cash Flow Reinvestment Rate (2007–2025)
Historical reinvestment intensity for Harbin Gloria Pharmaceuticals across 19 annual periods. Also explore 002437 current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Harbin Gloria Pharmaceuticals (2007–2025)
Year-by-year capital reinvestment analysis for Harbin Gloria Pharmaceuticals. For live market cap and broader valuation context, see market value of Harbin Gloria Pharmaceuticals.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.26x | CN¥343.47 Million | CN¥273.36 Million | CN¥23.81 Million | ▲ +589.1% |
| 2024 | 0.18x | CN¥74.93 Million | CN¥410.94 Million | CN¥62.90 Million | ▼ -59.7% |
| 2023 | 0.45x | CN¥124.00 Million | CN¥274.18 Million | CN¥29.62 Million | ▼ -53.9% |
| 2022 | 0.98x | CN¥256.90 Million | CN¥261.62 Million | CN¥33.01 Million | ▲ +306.9% |
| 2021 | 0.24x | CN¥66.17 Million | CN¥274.18 Million | CN¥34.51 Million | ▼ -94.4% |
| 2020 | 4.29x | CN¥54.70 Million | CN¥12.76 Million | CN¥43.66 Million | ▲ +1995.1% |
| 2019 | 0.20x | CN¥124.85 Million | CN¥610.37 Million | CN¥48.43 Million | ▼ -33.3% |
| 2018 | 0.31x | CN¥356.67 Million | CN¥1.16 Billion | CN¥104.34 Million | ▼ -30.0% |
| 2017 | 0.44x | CN¥285.52 Million | CN¥651.80 Million | CN¥194.63 Million | ▲ +14.4% |
| 2016 | 0.38x | CN¥398.39 Million | CN¥1.04 Billion | CN¥185.34 Million | ▼ -39.2% |
| 2015 | 0.63x | CN¥442.37 Million | CN¥702.05 Million | CN¥283.10 Million | ▲ +237.4% |
| 2014 | 0.19x | CN¥125.89 Million | CN¥674.04 Million | CN¥125.89 Million | ▼ -48.2% |
| 2013 | 0.36x | CN¥163.35 Million | CN¥453.02 Million | CN¥163.35 Million | ▼ -48.6% |
| 2012 | 0.70x | CN¥144.37 Million | CN¥205.89 Million | CN¥144.37 Million | ▼ -46.0% |
| 2011 | 1.30x | CN¥166.90 Million | CN¥128.61 Million | CN¥166.90 Million | ▼ -39.3% |
| 2010 | 2.14x | CN¥240.88 Million | CN¥112.59 Million | CN¥240.88 Million | ▲ +494.5% |
| 2009 | 0.36x | CN¥61.47 Million | CN¥170.82 Million | CN¥61.47 Million | ▼ -45.4% |
| 2008 | 0.66x | CN¥38.08 Million | CN¥57.81 Million | CN¥38.08 Million | ▲ +161.3% |
| 2007 | 0.25x | CN¥13.17 Million | CN¥52.26 Million | CN¥13.17 Million | — |